Firefly Neuroscience, Inc. (AIFF)
Firefly Neuroscience, Inc. operates in the Software - Application industry of the Technology sector, headquartered in Kenmore, NY, US. The stock last traded at $1.16, up 1.75% on the session, giving a market capitalisation of $17.2M. On trailing twelve-month figures it carries a trailing P/E of -1.71, a net margin of -565.4%. Its beta of 0.55 implies it has historically moved less than the broad market.
Based in Toronto, Canada, Firefly Neuroscience, Inc. is a medical technology and artificial intelligence firm specializing in developing neuroscientific solutions. The company's primary goal is to enhance patient outcomes for individuals affected by mental illnesses and neurological disorders. Its flagship product, Brain Network Analytics, is a sophisticated software platform engineered to aid in the diagnosis and treatment of a diverse range of cognitive and psychiatric conditions. These conditions encompass, but are not limited to, depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. Firefly Neuroscience, Inc. caters to both pharmaceutical companies and medical practitioners.
Firefly Neuroscience, Inc. is most often compared with the following Technology names: